Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Characterization of the PKPD relationship of reduced cholesterolemia by the peptide PCSK9-LDL receptor protein-protein interaction inhibitor P7 in mice and non-human primates

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: BUETERS, Tjerk (Merck & Co, Inc, PPDM, Westpoint, United States)
  • Co-author(s): Tjerk Bueters: PPDM, Merck & Co, Inc, Westpoint, PA, United States
    Kenneth Koeplinger: PPDM, Merck & Co, Inc, Westpoint, PA, United States
    Philippe Costet: Department of Cardiometabolic Diseases, Merck & Co, Inc, Kenilworth, NJ, United States
    Beth Murphy: Department of In Vivo Pharmacology, Merck & Co, Inc, Kenilworth, NJ, United States
    Scott Salowe: Department of In VitroPharmacology, Merck & Co, Inc, Kenilworth, NJ, United States
    Hratch Zokian: Department of In VitroPharmacology, Merck & Co, Inc, Kenilworth, NJ, United States
    Michael Kavana: Department of In VitroPharmacology, Merck & Co, Inc, Kenilworth, NJ, United States
    Candice Alleyne: Department of Discovery Pharmaceutical Sciences, Merck & Co, Inc, Kenilworth, NJ, United States
    Annette Bak: Department of Discovery Pharmaceutical Sciences, Merck & Co, Inc, Kenilworth, NJ, United States
    Sheng-Ping Wang: Department of Cardiometabolic Diseases, Merck & Co, Inc, Kenilworth, NJ, United States
    Yongcheng Huang: Department of Cardiometabolic Diseases, Merck & Co, Inc, Kenilworth, NJ, United States
    Angela Kerekes: Discovery Chemistry, Merck & Co, Inc, Kenilworth, NJ, United States
    James Tata: Discovery Chemistry, Merck & Co, Inc, Kenilworth, NJ, United States
    Yusheng Xiong: Discovery Chemistry, Merck & Co, Inc, Kenilworth, NJ, United States
    Shirly Pinto: Department of Cardiometabolic Diseases, Merck & Co, Inc, Kenilworth, NJ, United States
  • Abstract:

    Backgrounds

    PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is a clinically and genetically validated target to effectively reduce elevated LDL-c levels. Anti-PCSK9 antibody therapies (Repatha/Amgen, Praluent/Sanofi-Regeneron) have recently been approved as adjunct to diet and maximally tolerated statin therapy for patients suffering from..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses